Gilead Sciences Inc
Symbol: GILD (NASDAQ)
123.17
▲ (0.04%) 0.055
Company Description:
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
Key Stats
- Today's Open: $123.27
- Today's High: $124.602
- Today's Low: $121.953
- Today's Volume: 5.56M
- Yesterday Close: $123.11
- Yesterday High: $123.99
- Yesterday Low: $122.2
- Yesterday Volume: 8.15M
- Last Min Volume: 382
- Last Min High: $123.165
- Last Min Low: $123.165
- Last Min VWAP: $123.165
Company Profile
- Name: Gilead Sciences Inc
- Website: https://www.gilead.com
- Listed Date: 1992-01-22
- Location: FOSTER CITY, CA
- Market Status: Active
- CIK Number: 0000882095
- SIC Code: 2836
- SIC description: BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
- Market Cap: $152.76B
- Round Lot: 100
- Outstanding Shares: 1.24B
- Asset Type: CS
RECENT FILINGS FOR GILD
| Filing Date | Filing Type | Format |
|---|---|---|
| 2025-10-16 | 4 | View |
| 2025-10-16 | 4 | View |
| 2025-10-15 | 144 | View |
| 2025-10-15 | 144 | View |
| 2025-10-06 | 8-K | View |
| 2025-10-03 | 4 | View |
| 2025-09-30 | 4 | View |
| 2025-09-29 | 144 | View |
| 2025-09-23 | 4 | View |
| 2025-09-23 | 3 | View |
| 2025-09-16 | 4 | View |
| 2025-09-16 | 4 | View |
| 2025-09-15 | 144 | View |
| 2025-09-15 | 144 | View |
| 2025-09-11 | 4 | View |
| 2025-09-11 | 4 | View |
| 2025-09-11 | 4 | View |
| 2025-09-11 | 4 | View |
| 2025-09-11 | 4 | View |
| 2025-08-29 | 4 | View |
Latest News on GILD